Overview

Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

Status:
Terminated
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial of LMTM continued access to therapy and to evaluate the long-term safety of LMTM.
Phase:
Phase 3
Details
Lead Sponsor:
TauRx Therapeutics Ltd